ReP USP - Resultado da busca

Artigo de periodico
Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension (2022)
Souza, Rogerio de ; Delcroix, Marion; Galie, Nazzareno; Jansa, Pavel; Mehta, Sanjay; Pulido, Tomas; Rubin, Lewis; Sastry, B. K. S; Simonneau, Gerald; Sitbon, Olivier
Fonte: Advances in therapy. Unidade: FM
Assuntos: ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR, TERAPIA COMBINADA, SOBREVIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Rogerio de et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, v. 39, n. 9, p. 4374-4390, 2022Tradução . . Disponível em: https://doi.org/10.1007/s12325-022-02199-x. Acesso em: 16 maio 2024.
APA
Souza, R. de, Delcroix, M., Galie, N., Jansa, P., Mehta, S., Pulido, T., et al. (2022). Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Advances in therapy, 39( 9), 4374-4390. doi:10.1007/s12325-022-02199-x
NLM
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2024 maio 16 ] Available from: https://doi.org/10.1007/s12325-022-02199-x
Vancouver
Souza R de, Delcroix M, Galie N, Jansa P, Mehta S, Pulido T, Rubin L, Sastry BKS, Simonneau G, Sitbon O. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension [Internet]. Advances in therapy. 2022 ; 39( 9): 4374-4390.[citado 2024 maio 16 ] Available from: https://doi.org/10.1007/s12325-022-02199-x
Artigo de periodico
Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension (2019)
Torbicki, Adam; Bacchi, Marisa; Delcroix, Marion; Farber, Harrison W; Ghofrani, Hossein-Ardeschir; Hennessy, Brian; Jansa, Pavel; Mehta, Sanjay; Perchenet, Loic; Souza, Rogério
Fonte: Circulation-cardiovascular quality and outcomes. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR, DOENÇAS RARAS, SOBREVIDA, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TORBICKI, Adam et al. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension. Circulation-cardiovascular quality and outcomes, v. 12, n. 5, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCOUTCOMES.118.005095. Acesso em: 16 maio 2024.
APA
Torbicki, A., Bacchi, M., Delcroix, M., Farber, H. W., Ghofrani, H. -A., Hennessy, B., et al. (2019). Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension. Circulation-cardiovascular quality and outcomes, 12( 5). doi:10.1161/CIRCOUTCOMES.118.005095
NLM
Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani H-A, Hennessy B, Jansa P, Mehta S, Perchenet L, Souza R. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension [Internet]. Circulation-cardiovascular quality and outcomes. 2019 ; 12( 5):[citado 2024 maio 16 ] Available from: https://doi.org/10.1161/CIRCOUTCOMES.118.005095
Vancouver
Torbicki A, Bacchi M, Delcroix M, Farber HW, Ghofrani H-A, Hennessy B, Jansa P, Mehta S, Perchenet L, Souza R. Integrating data from randomized controlled trials and observational studies to assess survival in rare diseases insights from pulmonary arterial hypertension [Internet]. Circulation-cardiovascular quality and outcomes. 2019 ; 12( 5):[citado 2024 maio 16 ] Available from: https://doi.org/10.1161/CIRCOUTCOMES.118.005095
Artigo de periodico
Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (2017)
Mehta, Sanjay; Sastry, Bhagavatula Kutumba Srinivasa; Souza, Rogério; Torbicki, Adam; Ghofrani, Hossein-Ardeschir; Channick, Richard N.; Delcroix, Marion; Pulido, Tomás; Simonneau, Gérald; Wlodarczyk, John; Rubin, Lewis J.; Jansa, Pavel; Hunsche, Elke; Galiè, Nazzareno; Perchenet, Loïc; Sitbon, Olivier
Fonte: CHEST. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR, QUALIDADE DE VIDA, FARMACOTERAPIA, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MEHTA, Sanjay et al. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, v. 151, n. 1, p. 106-118, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.chest.2016.08.1473. Acesso em: 16 maio 2024.
APA
Mehta, S., Sastry, B. K. S., Souza, R., Torbicki, A., Ghofrani, H. -A., Channick, R. N., et al. (2017). Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. CHEST, 151( 1), 106-118. doi:10.1016/j.chest.2016.08.1473
NLM
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Vancouver
Mehta S, Sastry BKS, Souza R, Torbicki A, Ghofrani H-A, Channick RN, Delcroix M, Pulido T, Simonneau G, Wlodarczyk J, Rubin LJ, Jansa P, Hunsche E, Galiè N, Perchenet L, Sitbon O. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial [Internet]. CHEST. 2017 ; 151( 1): 106-118.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.chest.2016.08.1473
Artigo de periodico
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension (2017)
Galiè, Nazzareno; Jansa, Pavel; Pulido, Tomás; Channick Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Le Brun, Franck-Olivier; Mehta, Sanjay; Perchenet, Loïc; Rubin Lewis J.; Sastry, B.K.S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam
Fonte: European Heart Journal. Unidade: FM
Assuntos: MORTALIDADE, CATETERISMO CARDÍACO, ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GALIÈ, Nazzareno et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, v. 38, n. 15, p. 1147-1155, 2017Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehx025. Acesso em: 16 maio 2024.
APA
Galiè, N., Jansa, P., Pulido, T., Channick Richard N.,, Delcroix, M., Ghofrani, H. -A., et al. (2017). SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 38( 15), 1147-1155. doi:10.1093/eurheartj/ehx025
NLM
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2024 maio 16 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Vancouver
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2024 maio 16 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Artigo de periodico
Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN (2015)
Simonneau, Gérald; Channick, Richard N.; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Le Brun, Franck-Olivier; Mehta, Sanjay; Perchenet, Loic; Pulido, Tomás; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam; Rubin, Lewis J.
Fonte: European respiratory journal. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR, ESTUDOS DE COORTES, FÁRMACOS (SISTEMA RESPIRATÓRIO), ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SIMONNEAU, Gérald et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European respiratory journal, v. 46, n. 6, p. 1711-1720, 2015Tradução . . Disponível em: https://doi.org/10.1183/13993003.00364-2015. Acesso em: 16 maio 2024.
APA
Simonneau, G., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H. -A., Jansa, P., et al. (2015). Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. European respiratory journal, 46( 6), 1711-1720. doi:10.1183/13993003.00364-2015
NLM
Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Souza R, Torbicki A, Rubin LJ. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN [Internet]. European respiratory journal. 2015 ; 46( 6): 1711-1720.[citado 2024 maio 16 ] Available from: https://doi.org/10.1183/13993003.00364-2015
Vancouver
Simonneau G, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry BKS, Sitbon O, Souza R, Torbicki A, Rubin LJ. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN [Internet]. European respiratory journal. 2015 ; 46( 6): 1711-1720.[citado 2024 maio 16 ] Available from: https://doi.org/10.1183/13993003.00364-2015
Artigo de periodico
Effect of macitentan on hospitalizations: Results from the SERAPHIN trial (2015)
Channick, Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Hunsche, Elke; Jansa, Pavel; Le Brun, Franck-Olivier; Mehta, Sanjay; Pulido, Tomás; Rubin, Lewis J.; Sastry, B. K. S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério de; Torbicki, Adam; Galiè, Nazzareno
Fonte: JACC Heart failure. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR, FÁRMACOS/SISTEMA RESPIRATÓRIO, HOSPITALIZAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHANNICK, Richard N. et al. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial. JACC Heart failure, v. 3, n. 1, p. 1-8, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2014.07.013. Acesso em: 16 maio 2024.
APA
Channick, R. N., Delcroix, M., Ghofrani, H. -A., Hunsche, E., Jansa, P., Le Brun, F. -O., et al. (2015). Effect of macitentan on hospitalizations: Results from the SERAPHIN trial. JACC Heart failure, 3( 1), 1-8. doi:10.1016/j.jchf.2014.07.013
NLM
Channick RN, Delcroix M, Ghofrani H-A, Hunsche E, Jansa P, Le Brun F-O, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R de, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial [Internet]. JACC Heart failure. 2015 ; 3( 1): 1-8.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.jchf.2014.07.013
Vancouver
Channick RN, Delcroix M, Ghofrani H-A, Hunsche E, Jansa P, Le Brun F-O, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R de, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial [Internet]. JACC Heart failure. 2015 ; 3( 1): 1-8.[citado 2024 maio 16 ] Available from: https://doi.org/10.1016/j.jchf.2014.07.013
Artigo de periodico
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension (2013)
Pulido, Tomás; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loïc; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gérald
Fonte: The New England Journal of Medicine. Unidade: FM
Assuntos: HIPERTENSÃO PULMONAR (MORTALIDADE), CATETERISMO CARDÍACO, CONDUTAS TERAPÊUTICAS, MEDICAMENTO (EFEITOS ADVERSOS), MÉTODO DUPLO-CEGO, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PULIDO, Tomás et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, v. 369, n. 9, p. 809-818, 2013Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917. Acesso em: 16 maio 2024.
APA
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H. -A., et al. (2013). Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, 369( 9), 809-818. doi:10.1056/NEJMoa1213917
NLM
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2024 maio 16 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917
Vancouver
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2024 maio 16 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917
Trabalho de evento-resumo periodico
Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy (2013)
Simonneau, Gérald; Channick, Richard; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein; Jansa, Pavel; Le Brun, Franck - Olivier; Mehta, Sanjay; Perchenet, Loic; Pulido, Tomas; Sastry, B.; Sitbon, Olivier; Torbicki, Adam; Rubin, Lewis
Fonte: Chest. Nome do evento: CHEST 2013 Annual Meeting Abstracts. Unidade: FM
Assuntos: PROGNÓSTICO, HIPERTENSÃO PULMONAR (TERAPIA), FATORES DE RISCO, FÁRMACOS (SISTEMA RESPIRATÓRIO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SIMONNEAU, Gérald et al. Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. Chest. Chicago: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3. Acesso em: 16 maio 2024. , 2013
APA
Simonneau, G., Channick, R., Delcroix, M., Galiè, N., Ghofrani, H., Jansa, P., et al. (2013). Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy. Chest. Chicago: Faculdade de Medicina, Universidade de São Paulo. doi:10.1378/chest.1701395
NLM
Simonneau G, Channick R, Delcroix M, Galiè N, Ghofrani H, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry B, Sitbon O, Torbicki A, Rubin L. Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy [Internet]. Chest. 2013 ; 144( 4): 876A.[citado 2024 maio 16 ] Available from: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3
Vancouver
Simonneau G, Channick R, Delcroix M, Galiè N, Ghofrani H, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry B, Sitbon O, Torbicki A, Rubin L. Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy [Internet]. Chest. 2013 ; 144( 4): 876A.[citado 2024 maio 16 ] Available from: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3
Trabalho de evento-resumo periodico
Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan (2013)
Channick, Richard; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein A.; Jansa, Pavel; Le Brun, Franck - Olivier; Mehta, Sanjay; Perchenet, Loic; Pulido, Tomas; Souza, Rogério; Sastry, B.; Sitbon, Olivier; Torbicki, Adam; Rubin, Lewis; Simonneau, Gérald
Fonte: Chest. Nome do evento: CHEST 2013 Annual Meeting Abstracts. Unidade: FM
Assuntos: ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR, FATORES DE RISCO, FÁRMACOS (SISTEMA RESPIRATÓRIO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHANNICK, Richard et al. Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan. Chest. Chicago: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3. Acesso em: 16 maio 2024. , 2013
APA
Channick, R., Delcroix, M., Galiè, N., Ghofrani, H. A., Jansa, P., Le Brun, F. -O., et al. (2013). Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan. Chest. Chicago: Faculdade de Medicina, Universidade de São Paulo. doi:10.1378/chest.1701395
NLM
Channick R, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Souza R, Sastry B, Sitbon O, Torbicki A, Rubin L, Simonneau G. Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan [Internet]. Chest. 2013 ; 144( 4): 870B.[citado 2024 maio 16 ] Available from: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3
Vancouver
Channick R, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Souza R, Sastry B, Sitbon O, Torbicki A, Rubin L, Simonneau G. Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan [Internet]. Chest. 2013 ; 144( 4): 870B.[citado 2024 maio 16 ] Available from: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3
Trabalho de evento-resumo periodico
Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan (2013)
Souza, Rogério; Channick, Richard; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein; Jansa, Pavel; Le Brun, Franck - Olivier; Mehta, Sanjay; Perchenet, Loic; Pulido, Tomas; Sastry, B.; Sitbon, Olivier; Torbicki, Adam; Rubin, Lewis; Simonneau, Gérald
Fonte: Chest. Nome do evento: CHEST 2013 Annual Meeting Abstracts. Unidade: FM
Assuntos: PROGNÓSTICO, HIPERTENSÃO PULMONAR, ESTUDOS RANDOMIZADOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOUZA, Rogério et al. Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. Chest. Chicago: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3. Acesso em: 16 maio 2024. , 2013
APA
Souza, R., Channick, R., Delcroix, M., Galiè, N., Ghofrani, H., Jansa, P., et al. (2013). Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan. Chest. Chicago: Faculdade de Medicina, Universidade de São Paulo. doi:10.1378/chest.1701714
NLM
Souza R, Channick R, Delcroix M, Galiè N, Ghofrani H, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry B, Sitbon O, Torbicki A, Rubin L, Simonneau G. Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan [Internet]. Chest. 2013 ; 144( 4): 879A.[citado 2024 maio 16 ] Available from: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3
Vancouver
Souza R, Channick R, Delcroix M, Galiè N, Ghofrani H, Jansa P, Le Brun F-O, Mehta S, Perchenet L, Pulido T, Sastry B, Sitbon O, Torbicki A, Rubin L, Simonneau G. Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan [Internet]. Chest. 2013 ; 144( 4): 879A.[citado 2024 maio 16 ] Available from: http://journal.publications.chestnet.org/solr/searchresults.aspx?q=rog%C3%A9rio%20souza&allJournals=1&restypeid=3

Unidades USP

ReP

Filtros

Autores

Assuntos

Título da fonte

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos